Neurocrine Biosciences, Inc. (NBIX)

Market Cap	14.08B
Revenue (ttm)	2.51B
Net Income (ttm)	348.30M
Shares Out	99.18M
EPS (ttm)	3.39
PE Ratio	41.88
Forward PE	16.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	981,330
Open	141.86
Previous Close	140.89
Day's Range	139.90 - 142.08
52-Week Range	84.23 - 154.61
Beta	0.28
Analysts	Strong Buy
Price Target	163.71 (+15.29%)
Earnings Date	Oct 29, 2025

About NBIX

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 23, 1996
• Employees: 1,800
• Stock Exchange: NASDAQ
• Ticker Symbol: NBIX
• Website: https://www.neurocrine.com

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.

Analyst Forecast

According to 17 analysts, the average rating for NBIX stock is "Strong Buy." The 12-month stock price target is $163.71, which is an increase of 15.29% from the latest price.

Price Target

$163.71

(15.29% upside)

Analyst Consensus: Strong Buy